New Study Finds Paragonix SherpaPak System Significantly Improves 4-Year Survival Rates in Heart Transplant Patients
Landmark Study Demonstrates Significant 4-Year Survival Benefit in Heart Transplant Patients Using Paragonix SherpaPak System Paragonix Technologies, a pioneer in advanced organ transplant preservation and organ procurement services, has announced compelling new clinical evidence demonstrating improved long-term outcomes for heart…
U.S. Cryogenic Biobanking Market Outlook 2025–2030: Cord Blood Drives Innovation
U.S. Cryogenic Biobanking Services Market Forecast 2025–2030: Innovation Driven by Cord Blood Conservation and Personalized Medicine Industry Outlook & Forecast 2025-2030” from ResearchAndMarkets.com presents a comprehensive analysis of one of the most rapidly evolving segments within the life sciences industry.…
City of Hope® Patients Reunite with Lifesaving Blood Stem Cell Donors at Annual BMT Reunion
In March 2022, Nick De Graw, a 20-year-old sophomore majoring in mechanical engineering at the University of California, Irvine, noticed some unusual symptoms that led him to believe he might have contracted mononucleosis. For weeks, he experienced persistent night sweats…
AbCellera Unveils Promising Preclinical Data on PSMA x CD3 T-Cell Engagers at AACR 2025
AbCellera Presents Promising Preclinical Data Demonstrating Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025 AbCellera Biologics Inc. (Nasdaq: ABCL), a leading technology company specializing in the discovery and development of antibody-based therapeutics, has unveiled compelling preclinical data supporting…
Innate Pharma Reports Strong Preclinical Anti-Tumor Activity of IPH4502 Antibody-Drug Conjugate at AACR 2025
Innate Pharma Presents Compelling Preclinical Data on Novel ADC Candidate IPH4502 Targeting Nectin-4 at AACR 2025 Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA), a biotechnology company specializing in the development of immunotherapies for cancer, has unveiled promising new preclinical…
SOTIO Highlights Promising Preclinical Data for SOT109 and SOT106 in Solid Tumors
SOTIO Unveils Promising Preclinical Data for ADC Candidates SOT109 and SOT106, Signaling Best-in-Class Potential for Solid Tumor Therapies SOTIO Biotech, a clinical-stage biotechnology company and part of the PPF Group, has presented compelling preclinical data for two of its leading…
U.S. Patent Office Sides with BeiGene, Voids Pharmacyclics Patent
USPTO Invalidates Pharmacyclics Patent Challenged by BeiGene in BRUKINSA Dispute In a significant development in the ongoing intellectual property battle between two major players in the oncology therapeutics market, BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global biotechnology…
Titan Medical Group Unveils Titan Workforce Solutions to Revolutionize Healthcare Staffing
Titan Medical Group Launches Titan Workforce Solutions to Revolutionize Healthcare Staffing Nationwide Titan Medical Group, a leading name in the healthcare staffing industry, is proud to announce the official launch of Titan Workforce Solutions, a cutting-edge Managed Service Provider (MSP)…
AtriCure Announces First Quarter 2025 Financial Results
AtriCure Reports Strong First Quarter 2025 Financial Results Driven by Product Innovation and Market Expansion AtriCure, Inc. (Nasdaq: ATRC), a global leader in developing innovative surgical solutions for the treatment of atrial fibrillation (Afib), left atrial appendage (LAA) management, and…
Xencor Reports Positive Interim Results for XmAb942 in First Human Study
Xencor Reports Positive Interim Data From First-in-Human Study of XmAb942, Plans Phase 2b Trial for Inflammatory Bowel Disease Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company specializing in the development of engineered monoclonal antibodies and cytokines to treat cancer and…
QIAGEN Unveils New Lentivirus Tools to Advance Quality Control in Cell and Gene Therapy
QIAGEN Expands Digital PCR Portfolio With Advanced Lentivirus Solutions to Elevate Quality Control in Cell and Gene Therapy Manufacturing QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA), a global leader in sample and assay technologies for molecular diagnostics and life sciences,…
Sage Therapeutics Delivers Q1 2025 Results, Showcases Pipeline Progress and Strategic Developments
Sage Therapeutics Reports First Quarter 2025 Financial Results, Showcases Strong Momentum for ZURZUVAE and Pipeline Advancements Sage Therapeutics, Inc. (Nasdaq: SAGE) has announced its financial results for the first quarter ended March 31, 2025, highlighting solid progress in the commercialization…